|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related NESP inj[耐血比 注射劑 "台灣協和醱酵麒麟"] information |
|
|
|
製造商 |
Kyowa Hakko Kirin (Taiwan) |
|
代理/經銷商 |
Kyowa Hakko Kirin (Taiwan) |
|
成份 |
Darbepoetin α |
|
適應症 |
Treatment of anemia associated with chronic renal failure (CRF), including patients either on or not on dialysis. Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. |
|
用量 |
CRF patients Administered either IV/SC as a single weekly injection. Dose should be started & slowly adjusted to achieve & maintain a target Hb 10-12 g/dL. Reduce dose by 25% if rise in Hb is > 1 g/dL in 2 weeks. Correction of anemia Adult Initially 0.45 mcg/kg as single SC/IV once weekly. Maintain a target Hb 10-12 g/dL. Conversion From epoetin α to NESP Starting weekly dose should be estimated on the basis of the weekly epoetin α dose at the time of substitution. Administer once weekly if a patient was receiving epoetin α 2-3 times weekly. Administer once every 2 weeks if a patient was receiving epoetin α once weekly. Cancer patients receiving chemotherapy 2.25 mcg/kg once weekly. Increase dose to 4.5 mcg/kg if the rise in Hb is > 1 g/dL after 6 weeks. Refer full prescribing information for dosage adjustment. |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
禁忌 |
Uncontrolled HTN. |
|
注意事項 |
Closely monitor & control BP during therapy. Folic acid or vit B12 deficiencies, intercurrent infections, inflammatory or malignant processes, osteofibrosis cystica, occult blood loss, hemolysis, severe aluminum toxicity & bone marrow fibrosis may compromise the erythropoietic response. Pregnancy & lactation. |
|
不良反應 |
Vascular thrombosis, CHF, sepsis, cardiac arrhythmia, infections, HTN, hypotension, myalgia, headache, diarrhea, fever, nausea, chest pain.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
NESP 注射劑 |
|
NESP (Pre-filled syringe) 10 mcg x 1 mL |
|
NESP (Pre-filled syringe) 15 mcg x 1 mL |
|
NESP (Pre-filled syringe ) 20 mcg x 1 mL |
|
NESP (Pre-filled syringe ) 30 mcg x 1 mL |
|
NESP (Pre-filled syringe) 40 mcg x 1 mL |
|
NESP (Pre-filled syringe) 60 mcg x 1 mL |
|
NESP (Pre-filled syringe ) 120 mcg x 1 mL |
|
|
|
Manufacturer: |
Kyowa Hakko Kirin (Taiwan) |
|
Distributor: |
Kyowa Hakko Kirin (Taiwan)
|
|
|
|
